PTSD is the foundation indication for MDMA-assisted therapy — and MDMA-AT for PTSD is the strongest published evidence base in psychedelic medicine for any condition. The two anchor trials, Mitchell et al. 2021 Nature Medicine MAPP1 Phase 3 and Mitchell et al. 2023 Nature Medicine MAPP2 Phase 3, demonstrated effect sizes of approximately d=0.91 and d=1.0 on the Clinician-Administered PTSD Scale (CAPS-5) — substantially larger than published ketamine PTSD effect sizes (Bryant 2024 meta-analysis g≈0.20 bias-corrected) and exceeding standard PTSD pharmacotherapy effect sizes. Earlier Phase 2 work (Mithoefer 2018 Lancet Psychiatry in military veterans, firefighters, and police) demonstrated efficacy specifically in service-connected PTSD populations. Canadian access is SAP-only under the January 5, 2022 Health Canada amendment; Lykos Therapeutics' MDMA-AT for PTSD application was declined by the FDA in August 2024 via Complete Response Letter, and Lykos is pursuing additional Phase 3 trials. The Canadian SAP pathway operates independently of the FDA decision. Veterans Affairs Canada considers MDMA-AT case-by-case for service-related PTSD where SAP-approved — the most accessible coverage pathway given service-connected PTSD prevalence. This article walks through the evidence honestly, the comparison to ketamine PTSD evidence (the realistic alternative for many Canadian patients), and how ATMA CENA supports SAP-pathway MDMA-AT for PTSD.

Key takeaways

Strongest psychedelic medicine RCT base: Mitchell 2021 MAPP1 (N=90, d≈0.91) and Mitchell 2023 MAPP2 (N=104, d≈1.0) Phase 3 trials in Nature Medicine.

Service-connected PTSD evidence: Mithoefer 2018 Lancet Psychiatry Phase 2 in military veterans, firefighters, police demonstrated efficacy.

Effect sizes substantially larger than ketamine PTSD: ketamine PTSD pooled meta-analytic g≈0.20 bias-corrected (Bryant 2024); MDMA Phase 3 d≈0.91–1.0.

Standard protocol: 3 dosing sessions over ~12 weeks; 80 mg + optional 40 mg booster; 2 therapists; preparation + integration sessions before/after each dose.

Canadian access: SAP-only since January 5, 2022. ~41 cumulative MDMA SAP approvals as of February 2024 (vs ~176 psilocybin).

VAC considers MDMA-AT case-by-case for service-related PTSD where SAP-approved — most accessible Canadian coverage pathway.

August 2024 FDA decision on Lykos's MDMA-AT for PTSD application has not changed Canadian SAP-pathway operations but has added regulatory uncertainty about future formal approval.

For Canadian patients, the realistic decision is often MDMA-AT (stronger PTSD-specific evidence; SAP-only; higher cost; access-limited) versus ketamine therapy (broader Canadian access; smaller PTSD effect sizes; VAC and WSIB coverage; off-label legal).

What the evidence actually shows

Mitchell 2021 MAPP1 — the first Phase 3

Mitchell et al. 2021, Nature Medicine — MAPP1 — randomized double-blind Phase 3 RCT in 90 patients with severe PTSD. Protocol:

Three MDMA dosing sessions over ~12 weeks: 80 mg followed by optional 40 mg booster ~90 minutes later (or inactive placebo with same psychotherapy structure).
Bookended by structured psychotherapy: 3 preparation sessions before the first dose; 3 integration sessions after each dosing day (9 integration total).
Two trained therapists present during each dosing session.
Primary outcome: change in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5).

Findings:

Effect size d≈0.91 on CAPS-5 — large effect.
~67% of MDMA-AT participants no longer met PTSD diagnostic criteria at end of treatment, versus ~32% in placebo arm.
Clinically meaningful response in severe PTSD population that had failed prior treatments.
Acceptable safety profile across the trial.

This was the first Phase 3 confirmation of MDMA-AT efficacy in severe PTSD.

Mitchell 2023 MAPP2 — confirmatory Phase 3

Mitchell et al. 2023, Nature Medicine — MAPP2 — confirmatory randomized Phase 3 RCT in 104 patients with moderate-to-severe PTSD. Same protocol structure. Findings:

Effect size d≈1.0 — confirmatory and slightly larger than MAPP1.
Similar response rates across moderate-to-severe PTSD.
Sustained benefits at follow-up assessments.
Acceptable safety profile.

The MAPP1 + MAPP2 combined evidence base is the largest published psychedelic-assisted therapy RCT base for any condition. The effect sizes (d≈0.91–1.0) exceed standard PTSD pharmacotherapy effect sizes (typical SSRI effect sizes for PTSD are d≈0.3–0.5).

Mithoefer 2018 — Phase 2 in service-connected populations

Mithoefer et al. 2018, Lancet Psychiatry — Phase 2 RCT specifically in military veterans, firefighters, and police officers with chronic PTSD. The trial enrolled the population most relevant to Canadian VAC and workers' compensation pathways. Findings:

Significant reduction in CAPS-IV scores at primary endpoint
Sustained benefit at 12-month follow-up
Acceptable safety profile in service-connected population

This is the most directly applicable trial for Canadian veterans pursuing the VAC MDMA-AT pathway.

Earlier work — Mithoefer 2010 and Bouso

Mithoefer et al. 2010, J Psychopharmacology — the first MAPS-sponsored open-label Phase 2 in chronic PTSD. Established the modern MDMA-AT protocol structure; demonstrated initial safety and efficacy.

Earlier Spanish work by Bouso et al. and other independent groups established mechanistic and safety foundations.

Long-term follow-up

Long-term follow-up of the MAPS-supported Phase 2 trials demonstrated durable response — many participants maintained PTSD symptom reductions years after completing the three-session course. This durability without ongoing maintenance dosing is a meaningful feature of the MDMA-AT protocol relative to many PTSD pharmacotherapies that require continuous daily dosing.

How does this compare to ketamine PTSD evidence?

This comparison matters because ketamine is the realistic alternative for many Canadian patients given access constraints.

MDMA Phase 3 vs ketamine PTSD meta-analysis

	MDMA-AT for PTSD	Ketamine for PTSD
Largest published RCT(s)	Mitchell 2021 MAPP1 N=90, Mitchell 2023 MAPP2 N=104 (Phase 3)	Feder 2014 N=41, Feder 2021 N=30 (smaller Phase 2)
Effect size on CAPS	d≈0.91 (MAPP1), d≈1.0 (MAPP2)	Pooled g≈0.27 (Bryant 2024 meta-analysis) declining to g≈0.20 bias-corrected
Active vs passive control	Active inactive placebo + same psychotherapy	Midazolam active control; effects shrink against active control
Sustained response	Years post-treatment in long-term follow-up	Median time-to-relapse ~27 days post-acute series (Feder 2021)
Sessions per program	3 dosing + 12 psychotherapy = ~15	6 dosing + integration; 4–8 in shorter protocols
Total program cost	CAD $7,500–$15,000	CAD $1,530–$6,930 (ATMA CENA KAT pricing)
Health Canada status	No approved indication; SAP-only	Off-label legal (anaesthetic approved); Spravato approved for TRD (not PTSD)
Coverage in Canada	VAC case-by-case for service-related PTSD; otherwise out-of-pocket	Broader VAC, WSIB Ontario, WCB Alberta pathways
Access	Limited; ~41 SAP approvals total since 2022	Wide; off-label clinics across Canada

The honest practical comparison

MDMA-AT has substantially stronger PTSD-specific RCT evidence: larger effect sizes, sustained response in long-term follow-up, demonstrated efficacy in service-connected populations.

Ketamine has broader Canadian access and lower cost: legal off-label availability, established VAC and workers' compensation pathways, lower per-program cost, faster acute response (hours vs weeks), and Health Canada-approved Spravato pathway with private insurance coverage for documented TRD.

The realistic Canadian decision for most PTSD patients in 2026:

If the patient has VAC or workers' compensation coverage and a willing prescribing physician with MDMA-AT training: MDMA-AT's evidence base supports it as the higher-evidence option, and the VAC case-by-case coverage pathway is real.
If the patient is paying privately: ketamine therapy's lower cost (CAD $1,530–$6,930 vs $7,500–$15,000) is often the deciding factor unless the patient specifically values MDMA-AT's stronger evidence base.
If access is a barrier (no SAP-trained prescriber locally; long timeline): ketamine therapy is far more accessible.
If the patient has comorbid TRD: ketamine often has broader applicability given its TRD evidence; CANMAT 2021 task force recommendation; ELEKT-D 2023 non-inferior to ECT.
Some patients pursue both at different times — e.g., ketamine for acute crisis stabilization, MDMA-AT later for trauma processing in a more stable phase.

For the cross-treatment deep dive, see MDMA vs Ketamine for PTSD (Wave 2 sibling). For ketamine PTSD evidence detail, see Ketamine Therapy for PTSD.

How MDMA-AT works for PTSD specifically

The therapeutic mechanism for PTSD specifically draws on MDMA's distinctive pharmacology:

Reduced amygdala reactivity to trauma cues

MDMA dampens amygdala response to threat cues during the dosing window. The amygdala is hyperreactive in PTSD; reducing this reactivity allows patients to engage with traumatic content without being overwhelmed by fear, dissociation, or autonomic arousal — a state often called the "extended therapeutic window."

Oxytocin-mediated relational opening

MDMA's significant oxytocin release reduces fear-of-attachment and supports therapeutic alliance. For trauma survivors whose relational capacities are often disrupted, the oxytocin effect creates conditions for the therapeutic relationship to deepen during dosing.

Active engagement during dosing

Unlike psilocybin (where therapists are predominantly quiet) or ketamine (where patients are often inward-focused), MDMA patients typically remain conversationally available and emotionally engaged during dosing. Therapists conduct active trauma-focused therapeutic work — narrative reconstruction, attachment repair, fear extinction work — in a state where the patient can do the work without becoming overwhelmed.

Prefrontal-amygdala reorganization post-dosing

Emerging neuroimaging evidence suggests that the post-dosing weeks involve enhanced prefrontal regulation of amygdala fear circuits — a mechanism that may explain the durability of response after only three dosing sessions.

Comparison to standard PTSD treatment mechanisms

SSRIs/SNRIs: monoamine modulation; 4–6 weeks for clinical effect; modest effect sizes; require ongoing daily dosing.
Trauma-focused psychotherapy (TF-CBT, PE, EMDR): exposure and processing; effective but requires substantial sessions and emotional capacity to engage with trauma content.
Ketamine: NMDA antagonism; rapid acute response; less specifically targeted at trauma processing.
MDMA-AT: serotonin/NE/oxytocin; creates state for active trauma processing within a structured 3-session protocol.

Eligibility and screening for MDMA-AT for PTSD

The screening framework is consistent across the cluster.

Generally eligible:

Adults 18 or older
DSM-5 PTSD diagnosis (severe per Mitchell MAPP1 inclusion criteria; moderate-to-severe per MAPP2)
Documented adequate trials of first-line treatments (TF-CBT, PE, EMDR, SSRIs/SNRIs)
Medically stable

Absolute contraindications:

Personal history of psychotic disorder
Recent or current mania/hypomania
Uncontrolled cardiovascular disease, recent MI, severe structural heart disease, significant arrhythmia
Pregnancy
Severe hepatic impairment
Concurrent MAOIs — absolute contraindication

Relative contraindications:

Active substance use disorder
High-dose serotonergic antidepressants (typically tapered before MDMA dosing under prescriber supervision)
Severe personality disorder with marked instability
Complex trauma without adequate therapeutic alliance and prep capacity

For the access pathway specifics, see How to Access MDMA-Assisted Therapy in Canada.

Veterans and first responders — the most accessible coverage pathway

Service-connected PTSD is a particularly significant indication for Canadian MDMA-AT given:

Mithoefer 2018 specifically demonstrated efficacy in this population (military veterans, firefighters, police)
Veterans Affairs Canada considers MDMA-AT case-by-case for service-related PTSD where SAP-approved — the most accessible Canadian coverage pathway
Provincial workers' compensation for first responders (police, paramedics, firefighters, corrections, dispatchers) under presumptive PTSD legislation in Ontario and Alberta — though formal MDMA listing is not in place; case-by-case review applies

For the veterans-specific pathway, see MDMA-Assisted Therapy for Veterans (Wave 2 sibling article).

How ATMA CENA supports SAP-pathway MDMA-AT patients

ATMA CENA's role is the same as for psilocybin SAP-pathway work:

ATMA CENA does not initiate SAP applications. The medical SAP request is initiated by the patient's prescribing physician or psychiatric consultant.
ATMA CENA supports preparation and integration through the three-phase model — particularly important given MDMA-AT's longer integration phase (9 sessions across the program).
The coordinated care model is especially relevant for trauma-focused work where the patient often has an established therapeutic alliance with a trauma-trained therapist. coordinated care lets that therapist remain primary while ATMA CENA's clinical infrastructure provides the dosing-specific frame.
ATMA CENA's training program prepares clinicians for psychedelic-assisted therapy work; MDMA-AT-specific training scope should be confirmed at intake.

Frequently asked questions

What's the strongest evidence for MDMA-AT in PTSD? Mitchell 2021 MAPP1 (Nat Med, N=90, d≈0.91) and Mitchell 2023 MAPP2 (Nat Med, N=104, d≈1.0) Phase 3 trials. Combined, the largest published psychedelic-assisted therapy RCT base for any condition.

How does MDMA-AT compare to ketamine for PTSD? MDMA-AT has substantially larger effect sizes in published Phase 3 trials. Ketamine has broader Canadian access (off-label legal), VAC and workers' compensation coverage, and lower cost. The realistic decision often turns on access, coverage, and clinical fit. See MDMA vs Ketamine for PTSD.

Is MDMA-AT approved for PTSD in Canada? No — psilocybin and MDMA both have no Health Canada approved indication. SAP is the only legal pathway. The August 2024 FDA Complete Response Letter on Lykos's MDMA-AT for PTSD application has added uncertainty about the formal approval timeline.

Does VAC cover MDMA-AT for veterans? Veterans Affairs Canada considers MDMA-AT case-by-case for service-related PTSD where SAP-approved. The most accessible Canadian coverage pathway for many patients. See MDMA-Assisted Therapy for Veterans.

How many sessions are typical? Three dosing sessions over ~12 weeks; 3 preparation sessions before; 3 integration sessions after each dosing day (9 total integration). ~24 sessions across the full program.

What if I've tried antidepressants and trauma-focused therapy and they didn't work? This is the standard Canadian SAP application profile. Documented failure of first-line treatments (TF-CBT, PE, EMDR; SSRIs/SNRIs at therapeutic dose for ≥6 weeks) supports SAP eligibility for severe or treatment-resistant PTSD.

Will I have to relive my trauma in detail during dosing? The MDMA experience supports therapeutic engagement with trauma content without overwhelm — the "extended therapeutic window." The therapy team works with the patient on the level of detail and approach. This is part of the preparation conversation.

What if I'm a first responder with workplace-related PTSD? Provincial presumptive PTSD legislation (Ontario, Alberta) accelerates eligibility for the underlying diagnosis but does not auto-approve MDMA-AT through workers' compensation. Case-by-case review applies. WSIB Ontario and WCB Alberta have established pathways for ketamine that may extend to MDMA case-by-case.

Can I keep taking my SSRI during the program? Most published protocols taper SSRIs before MDMA dosing — both because SSRIs may attenuate MDMA's serotonergic effects and because of theoretical serotonin syndrome considerations. This is a clinical decision with the prescribing physician.

What if my application is denied? Options include resubmitting with additional documentation, identifying a different prescriber, or pursuing alternative PTSD treatments. Ketamine Therapy for PTSD is the most accessible alternative with substantial published evidence and broader Canadian access pathways.

How do I find a SAP-trained MDMA-AT prescriber? TheraPsil maintains a directory and offers free patient consultations. MAPS Canada, Numinus-network providers, Quebec collective providers, and Roots to Thrive (Nanaimo BC) have SAP-pathway experience. ATMA CENA's intake call can orient you to appropriate Canadian resources.

Will I be able to stop my PTSD medications after MDMA-AT? This is a clinical question with your prescribing physician. Many MAPP1/MAPP2 long-term follow-up participants reported sustained PTSD symptom reduction without ongoing daily PTSD medications, but individual outcomes vary.

What's the durability of response after a three-session course? Long-term follow-up of MAPS-supported Phase 2 trials demonstrated sustained PTSD symptom reduction years after the three-session course. Mitchell 2021/2023 follow-up assessments showed sustained benefit. Individual durability varies; some patients later pursue additional sessions.

Sources

ATMA CENA — coordinated care: https://psychedelic.healthcare/find-care
Mitchell JM, et al. (2021). MDMA-assisted therapy for severe PTSD: MAPP1 Phase 3. Nat Med. https://pubmed.ncbi.nlm.nih.gov/33972795/
Mitchell JM, et al. (2023). MDMA-assisted therapy for moderate to severe PTSD: MAPP2 Phase 3. Nat Med. https://pubmed.ncbi.nlm.nih.gov/37709999/
Mithoefer MC, et al. (2018). Phase 2 RCT in military veterans, firefighters, police. Lancet Psychiatry. https://pubmed.ncbi.nlm.nih.gov/29728331/
Mithoefer MC, et al. (2010). The first MAPS-sponsored open-label Phase 2. J Psychopharmacol. https://pubmed.ncbi.nlm.nih.gov/20643699/
Sessa B, Higbed L, Nutt D (2019). A review of MDMA-assisted psychotherapy. Front Psychiatry. https://pubmed.ncbi.nlm.nih.gov/30916641/
Feder A, et al. (2014). Single-dose IV ketamine for chronic PTSD. JAMA Psychiatry. https://pubmed.ncbi.nlm.nih.gov/24740528/
Feder A, et al. (2021). Repeated ketamine for chronic PTSD. Am J Psychiatry. https://pubmed.ncbi.nlm.nih.gov/37404970/
Bryant J, et al. (2024). Meta-analysis of ketamine for PTSD RCTs. Eur J Psychotraumatol. https://pmc.ncbi.nlm.nih.gov/articles/PMC10791091/
Health Canada — SAP psychedelic-assisted psychotherapy: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html
Veterans Affairs Canada — Mental Health Benefits: https://www.veterans.gc.ca/en/financial-programs-and-services/medical-costs/coverage-services-prescriptions-and-devices/mental-health-benefits
WSIB Ontario — PTSD First Responders Policy: https://www.wsib.ca/en/operational-policy-manual/posttraumatic-stress-disorder-first-responders-and-other-designated
FDA Complete Response Letter on MDMA-AT for PTSD (August 2024): https://www.psychiatrictimes.com/view/fda-releases-complete-response-letter-on-declining-mdma-assisted-therapy-for-ptsd

MDMA-Assisted Therapy for PTSD

MDMA-assisted therapy remains investigational in many places